Pancreatic Cancer Risk in Patients With Low-Risk Cystic Lesions
JAMA Network Open · 20.05.2026 · 9 (5) · e2613808
DOI: 10.1001/jamanetworkopen.2026.13808 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.05.2026. Verfasst von Arya Haj Mirzaian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Pancreatic Cyst. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Low-risk pancreatic cystic lesions (PCLs) represent common incidental findings with potential for malignant transformation, warranting long-term surveillance. However, data on their long-term cancer risk are limited, leading to inconsistency in current surveillance strategies.
Objective
To determine the long-term incidence of pancreatic cancer among patients with low-risk PCLs, and to identify baseline clinical and imaging factors associated with cancer development. Design, Setting, and Participants This cohort study was conducted among adults (aged ≥18 years) who underwent contrast-enhanced abdominal computed tomography (CT) or magnetic resonance imaging (MRI) between January 1, 2009, and December 31, 2021, at a large, multisite health care system in Massachusetts. MRI or CT scans were screened for PCLs without high-risk stigmata, worrisome features, or coexisting pancreatic mass. Eligible patients with low-risk PCLs were longitudinally followed up. Data analysis was performed from February 2024 to May 2025. Exposures Baseline demographic, clinical, and imaging characteristics of patients with low-risk PCLs. Main Outcomes and Measures The outcome was incidence of pancreatic cancer (defined as pathologically confirmed adenocarcinoma, invasive mucinous neoplasms, or high-grade dysplasia). Censoring was defined as absence of pancreatic cancer on imaging follow-up for more than 1 year after the initial examination documenting the PCL. Multivariable cause-specific Cox proportional hazards regression models assessed the associations between baseline factors and incident pancreatic cancer, accounting for death as a competing risk. Associations were reported as hazard ratios (HRs). Risk stratification performance was assessed using Harrell C-statistic and net reclassification index (NRI).
Results
Among 499 631 patients reviewed, 6064 with low-risk PCLs were identified and included in the analytic sample, contributing 20 145 person-years of follow-up. Patients had a mean (SD) age at diagnosis of 65.9 (12.3) years and included 3612 females (59.6%). Of the 6064 patients, 38 (0.6%) developed pancreatic cancer, with an incidence rate of 1.89 (95% CI, 1.29-2.49) cases per 1000 person-years, which was higher than the previously reported general population rate of 0.14 cases per 1000 person-years. Twenty-six of 38 patients (68.4%) had cancer that arose from the cyst site, while 12 (31.6%) developed cancer from a different region of the pancreas. Ten patients (26.3%) were diagnosed more than 5 years after initial PCL detection. In multivariable analysis, larger cyst size (HR, 2.24; 95% CI, 1.45-3.48), main pancreatic duct ectasia (HR, 2.84; 95% CI, 1.18-6.84), and older age (HR, 1.04; 95% CI, 1.01-1.07) were associated with cancer. Adding age to a cyst size–based risk stratification model improved estimation of pancreatic cancer risk (NRI, 0.20 [95% CI, 0.03-0.37]; change in C-statistic, 0.14 [95% CI, 0.07-0.22]). Conclusions and Relevance This cohort study found that low-risk PCLs were associated with a sustained long-term pancreatic cancer risk and were best stratified by combining clinical and imaging factors. Longer than a 5-year follow-up of low-risk PCLs may be warranted to reduce missed or delayed diagnosis of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
- Department of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston.
- Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Haj Mirzaian, A., Abbasi, N., Kambadakone, A. R., Lacson, R., Hernandez-Barco, Y. G., Jin, D. X., Jajoo, K., Bates, D. W., & Khorasani, R. (2026). Pancreatic Cancer Risk in Patients With Low-Risk Cystic Lesions. JAMA Network Open, 9(5), e2613808. https://doi.org/10.1001/jamanetworkopen.2026.13808
Vancouver
Haj Mirzaian A, Abbasi N, Kambadakone AR, Lacson R, Hernandez-Barco YG, Jin DX, et al. Pancreatic Cancer Risk in Patients With Low-Risk Cystic Lesions. JAMA Network Open. 2026;9(5):e2613808. doi:10.1001/jamanetworkopen.2026.13808
BibTeX
@article{HajMirzaian2026,
author = {Haj Mirzaian, Arya and Abbasi, Nooshin and Kambadakone, Avinash R and Lacson, Ronilda and Hernandez-Barco, Yasmin G and Jin, David X and Jajoo, Kunal and Bates, David W and Khorasani, Ramin},
title = {Pancreatic Cancer Risk in Patients With Low-Risk Cystic Lesions},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {5},
pages = {e2613808},
doi = {10.1001/jamanetworkopen.2026.13808}
}
EUVIMED